- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01846650
A Bioequivalence Study of Capecitabine Tablets
September 28, 2013 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Bioequivalence Study of Capecitabine Tablets in Patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer
- purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG)
- Experimental Design: Two-period crossover design
- Test drug: Capecitabine tablets Reference drug: XELODA
- Sample size:24
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanxi
-
Xi an, Shanxi, China
- First Affiliated Hospital of Fourth Military Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have histopathologically /cytologically confirmed breast cancer or colorectal cancer,without chemotherapy or only adjuvant chemotherapy, and had previously received one or two standard chemotherapy regimens for patients;
- Age: 18-70 years, gender: both,BMI≥17,Eastern Cooperative Oncology Group (ECOG) performance status:0-2,Life expectancy greater than 3 months;
- Patients must have normal bone marrow function, liver and kidney function; adequate organ function in the last 1 week, meeting the following: ANC≥1.5×109/L,PLT≥80×109/L, Total bilirubin≤1.5×the upper limit of normal, ALT,AST≤2.5×the upper limit of normal, creatinine≤1.5×the institutional upper limit of normal.
- Patients who has retreatment could be enrolled at least 4 weeks after the last chemotherapy and radiotherapy.
- Patients must volunteer to participate and sign informed consent form.
Exclusion Criteria:
- Suffering from heart, liver, kidney disease or severe acute and Organ invasion disease;
- Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil, or known DPD (Dihydropyrimidine Dehydrogenase) deficiency.
- Pregnant or breast-feeding female
- Only bone metastasis lesions, no other measurable lesions
- Known brain metastasis or history of organ transplantation
- Have long-term systemic steroid therapy
- Serious diseases of vital organs; other malignancies which is not cure
- Use of chemotherapy in the last 4 weeks
- History of drug/alcohol addiction or a positive hepatitis screen including hepatitis B surface antigen, HCV or HAV (IgM) antibodies
- Patient having abnormal serum calcium level at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
- Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI CTCAE criteria or known, existing uncontrolled coagulopathy.
- Subjects are thought unsuitable for the study by investigators;
- Inability to comply with protocol or study procedures in the opinion of the investigator;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Capecitabine tablets
Single oral Capecitabine tablets 2000mg qd
|
Single oral Capecitabine tablets 2000mg qd
|
Active Comparator: XELODA
Single oral XELODA 2000mg qd
|
Single oral XELODA 2000mg qd
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under Curve (AUC)
Time Frame: predose, 0.33,0.67,1,1.5,2,2.5,3,4,5,6,8,hours post-dose
|
predose, 0.33,0.67,1,1.5,2,2.5,3,4,5,6,8,hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Wen Ai dong, doctor, First Affiliated Hospital of Fourth Military Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
May 1, 2013
First Submitted That Met QC Criteria
May 2, 2013
First Posted (Estimate)
May 3, 2013
Study Record Updates
Last Update Posted (Estimate)
October 1, 2013
Last Update Submitted That Met QC Criteria
September 28, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Breast Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Breast Neoplasms
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
Other Study ID Numbers
- KPTB-1.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer or Metastatic Colorectal Cancer
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Jules Bordet InstituteCompletedMetastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast CancersBelgium
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
University of OxfordoxBRC; Vodafone UK Foundation; Centre for Statistics in Medicine; Oncology Clinical...CompletedMetastatic Colorectal Cancer | Metastatic Breast CancerUnited Kingdom
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
Clinical Trials on Capecitabine tablets
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Bio-Thera SolutionsUnknownHER2-positive Advanced Breast CancerChina
-
Zhejiang UniversityGeneCast Biotechnology Co., Ltd.Not yet recruiting
-
Sun Yat-sen UniversityRecruitingMetastatic | Adenocarcinoma of Small Intestine | Appendix CarcinomaChina
-
Sun Yat-sen UniversityRecruiting
-
Assiut UniversityNot yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Gastric Adenocarcinoma and Esophageal Squamous Cell CarcinomaChina
-
Shanghai Miracogen Inc.RecruitingRecurrent or Metastatic Nasopharyngeal CarcinomaChina
-
UNICANCERNot yet recruitingTriple Negative Breast Neoplasms
-
UNICANCERSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Leptomeningeal Disease | Leptomeningeal MetastasisFrance